Education
About Us
Working with TipRanks
Follow Us
RxSight (RXST)
NASDAQ:RXST
Earnings Data
Report Date
May 12, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.31Last Year’s EPS
-0.2Same Quarter Last Year
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balanced picture: notable operational and clinical strengths (strong LAL margins, improving sequential LAL volumes, compelling clinical evidence, a growing installed base and a robust cash position) but also material near-term headwinds (large LDD revenue decline, a wider GAAP loss, manufacturing-driven margin pressure and conservative 2026 guidance). Management emphasized early signs of commercial improvement and a measured plan to drive utilization and international expansion, while remaining prudent in 2026 assumptions.Company Guidance
Strong LAL Revenue Mix and Gross Margin
LAL revenue was $28.2M in Q4 (in line with Q4 2024) and accounted for an all-time high 86% of total company sales in Q4 (up from 71% year-ago); Q4 gross margin improved to 77.5% vs 71.6% year-ago; full-year 2025 gross profit margin was 76.6% vs 70.7% in 2024.
Solid Full-Year Sales Growth
Full-year 2025 sales were $134.5M, an increase of 4% year-over-year, driven by a 12% increase in LAL sales despite a material LDD decline.
Expanding Installed Base
LDD installed base grew to 1,134 units at year-end 2025, up 17% from 971 at the end of 2024, providing a larger foundation to drive same-store utilization and LAL sales.
Clinical Validation and Large-Scale Data
Post-approval study accepted for publication showing 93% of LALs achieved both spherical equivalent and residual cylinder within 0.5D of target; a >20,000-eye registry presented supporting superior refractive accuracy and real-world outcomes.
Strong Liquidity and No Debt
Ended 2025 with approximately $228M in cash, cash equivalents and short-term investments and no debt, supporting continued investment and international expansion efforts.
Sequential Operational Improvement in Q4
Procedural volumes translated into Q4 LAL units of 28,611 (down 2% YoY but up 10% sequentially), and management reported improving utilization trends and early positive results from targeted commercial initiatives.
Ongoing Innovation and International Approvals
Company highlighted ~20 FDA approvals over the past 5 years, planned submissions over the next 18 months, and regulatory approvals in the EU, U.K., South Korea, Singapore, select ASEAN countries and Australia to support longer-term international growth.
RXST Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RXST Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $8.81 | $7.92 | -10.10% |
Nov 05, 2025 | $8.34 | $8.61 | +3.24% |
Aug 07, 2025 | $7.79 | $7.19 | -7.70% |
May 07, 2025 | $14.90 | $13.23 | -11.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does RxSight (RXST) report earnings?
RxSight (RXST) is schdueled to report earning on May 12, 2026, After Close (Confirmed).
What is RxSight (RXST) earnings time?
RxSight (RXST) earnings time is at May 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RXST EPS forecast?
RXST EPS forecast for the fiscal quarter 2026 (Q1) is -0.31.